Neurocrine Biosciences (NBIX) reported $959 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 39.5%. EPS of $2.85 for the same period compares to $1.06 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $901.54 million, representing a surprise of +6.37%. The company delivered an EPS surprise of +26.11%, with the consensus EPS estimate being $2.26.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...